Catalyst Wire Dossier Catalyst Wire Dossier

Adjuvanted Epstein-Barr virus glycoprotein 350 vaccine

Epstein-Barr virus glycoprotein 350 vaccine · National Institute of Allergy and Infectious Diseases (NIAID)
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Adjuvanted Epstein-Barr virus glycoprotein 350 vaccine, covering 2026-04-22 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons [Phase 1, Phase 2]

See pricing